[go: up one dir, main page]

CY1111644T1 - Τριαζολο [1,5-α] κινολινες ως συνδετες του υποδοχεα a3 της αδενοσινης - Google Patents

Τριαζολο [1,5-α] κινολινες ως συνδετες του υποδοχεα a3 της αδενοσινης

Info

Publication number
CY1111644T1
CY1111644T1 CY20111100519T CY111100519T CY1111644T1 CY 1111644 T1 CY1111644 T1 CY 1111644T1 CY 20111100519 T CY20111100519 T CY 20111100519T CY 111100519 T CY111100519 T CY 111100519T CY 1111644 T1 CY1111644 T1 CY 1111644T1
Authority
CY
Cyprus
Prior art keywords
solvates
isomers
oxides
salts
general formula
Prior art date
Application number
CY20111100519T
Other languages
English (en)
Inventor
Edit Susán
Kinga Boér
Zoltán Kapui
Géza Timári
Sándor Bátori
Zoltán Szlávik
Endre Mikus
Szeredi Judit Vargáné
Michel Finet
Szabó Katalin Urbán
Tibor Szabó
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1111644T1 publication Critical patent/CY1111644T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με τους συνδέτες του υποδοχέα Α3 της αδενοσίνης του γενικού χημικού τύπου (I), και μέσω αυτών και με τους ανταγωνιστές, με τα άλατα τους, τα επιδιαλυτωμένα χημικά σωματίδια τους, τα Ν-οξείδιά τους και τα ισομερή τους, με τις φαρμακευτικές συνθέσεις που περιέχουν τις ενώσεις του γενικού χημικού τύπου (I), τα άλατα τους, τα επιδιαλυτωμένα χημικά σωματίδια τους, τα Ν-οξείδιά τους και τα ισομερή τους, με τη χρήση των ενώσεων του γενικού χημικού τύπου (I), τα άλατα τους, τα επιδιαλυτωμένα χημικά σωματίδια τους, τα Ν-οξείδιά τους και τα ισομερή τους, με την παρασκευή των ενώσεων του γενικού χημικού τύπου (I), τα άλατα τους, τα επιδιαλυτωμένα χημικά σωματίδια τους, τα Ν-οξείδιά τους και τα ισομερή τους, καθώς και με τα νέα ενδιάμεσα των γενικών χημικών τύπων (II), (VI), (XI), (XII) και (XV), και με την παρασκευή αυτών.
CY20111100519T 2007-06-07 2011-05-30 Τριαζολο [1,5-α] κινολινες ως συνδετες του υποδοχεα a3 της αδενοσινης CY1111644T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700395A HUP0700395A2 (en) 2007-06-07 2007-06-07 Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP08762666A EP2167470B1 (en) 2007-06-07 2008-06-02 Triazolo [1, 5-a]quinolines as adenosine a3 receptor ligands

Publications (1)

Publication Number Publication Date
CY1111644T1 true CY1111644T1 (el) 2015-10-07

Family

ID=89987565

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100519T CY1111644T1 (el) 2007-06-07 2011-05-30 Τριαζολο [1,5-α] κινολινες ως συνδετες του υποδοχεα a3 της αδενοσινης

Country Status (44)

Country Link
US (1) US8338411B2 (el)
EP (1) EP2167470B1 (el)
JP (1) JP5487100B2 (el)
KR (1) KR20100031610A (el)
CN (1) CN101679272B (el)
AR (1) AR066873A1 (el)
AT (1) ATE502016T1 (el)
AU (1) AU2008259534B2 (el)
BR (1) BRPI0812257A2 (el)
CA (1) CA2689612A1 (el)
CL (1) CL2008001648A1 (el)
CO (1) CO6270233A2 (el)
CR (1) CR11171A (el)
CY (1) CY1111644T1 (el)
DE (1) DE602008005589D1 (el)
DK (1) DK2167470T3 (el)
DO (1) DOP2009000276A (el)
EC (1) ECSP099783A (el)
ES (1) ES2363672T3 (el)
GT (1) GT200900301A (el)
HN (1) HN2009003357A (el)
HR (1) HRP20110332T1 (el)
HU (1) HUP0700395A2 (el)
IL (1) IL202471A0 (el)
JO (1) JO2689B1 (el)
MA (1) MA31738B1 (el)
ME (1) ME00958B (el)
MX (1) MX2009013209A (el)
MY (1) MY148654A (el)
NI (1) NI200900210A (el)
NZ (1) NZ581186A (el)
PA (1) PA8782901A1 (el)
PE (1) PE20090325A1 (el)
PL (1) PL2167470T3 (el)
PT (1) PT2167470E (el)
RU (1) RU2489432C2 (el)
SI (1) SI2167470T1 (el)
SV (1) SV2009003420A (el)
TN (1) TN2009000482A1 (el)
TW (1) TWI424998B (el)
UA (1) UA99463C2 (el)
UY (1) UY31130A1 (el)
WO (1) WO2008149168A1 (el)
ZA (1) ZA200908280B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101722289B1 (ko) 2009-07-08 2017-03-31 데르미라 (캐나다), 인코포레이티드 피부과 질환 또는 증상의 치료에 유용한 ｔｏｆａ 유사체
FR3053968A1 (fr) * 2016-07-13 2018-01-19 Biomerieux Reactifs pour la protection reversible de molecules biologiques
CA3037588C (en) * 2016-09-24 2022-07-12 Kbp Biosciences Co., Ltd. Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
CR20230030A (es) 2018-02-27 2023-03-10 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2021000116A (es) 2018-07-05 2021-03-29 Incyte Corp Derivados de pirazina fusionados como inhibidores de a2a/a2b.
PE20211768A1 (es) 2018-11-30 2021-09-07 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso
BR112021011948A2 (pt) 2018-12-20 2021-09-08 Incyte Corporation Compostos de imidazopiridazina e imidazopiridina e usos dos mesmos
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
GR76063B (el) * 1981-04-03 1984-08-03 Roussel Uclaf
ZA836701B (en) * 1982-10-01 1984-10-31 Roussel Uclaf Imidazo(1,2-a)quinolines
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
CN1257160C (zh) * 2001-05-31 2006-05-24 赛诺菲-安万特公司 氨基喹啉衍生物和它们的作为腺苷a3配体的应用
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
AU2002361374A1 (en) 2001-12-21 2003-07-09 JSW-Research Forschungslabor GmbH% Pyrazolyl-substituted triazoloquinoxalines
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
WO2005009969A1 (en) * 2003-07-31 2005-02-03 Sanofi-Aventis Aminoquinoline derivatives and their use as adenosine a3 ligands

Also Published As

Publication number Publication date
CN101679272A (zh) 2010-03-24
IL202471A0 (en) 2010-06-30
PL2167470T3 (pl) 2011-08-31
TN2009000482A1 (en) 2011-03-31
MY148654A (en) 2013-05-15
BRPI0812257A2 (pt) 2014-12-23
JP2010529100A (ja) 2010-08-26
HUP0700395A2 (en) 2009-03-02
TWI424998B (zh) 2014-02-01
AR066873A1 (es) 2009-09-16
AU2008259534B2 (en) 2012-07-05
MA31738B1 (fr) 2010-10-01
AU2008259534A1 (en) 2008-12-11
CN101679272B (zh) 2013-02-06
RU2489432C2 (ru) 2013-08-10
NI200900210A (es) 2010-07-15
PA8782901A1 (es) 2009-01-23
US20100216786A1 (en) 2010-08-26
WO2008149168A1 (en) 2008-12-11
ECSP099783A (es) 2010-01-29
KR20100031610A (ko) 2010-03-23
RU2009149518A (ru) 2011-07-20
DOP2009000276A (es) 2010-01-31
JO2689B1 (en) 2013-03-03
SI2167470T1 (sl) 2011-06-30
UY31130A1 (es) 2009-01-30
NZ581186A (en) 2012-03-30
JP5487100B2 (ja) 2014-05-07
EP2167470B1 (en) 2011-03-16
US8338411B2 (en) 2012-12-25
UA99463C2 (en) 2012-08-27
GT200900301A (es) 2010-04-22
PE20090325A1 (es) 2009-04-17
CR11171A (es) 2010-04-21
TW200914451A (en) 2009-04-01
ATE502016T1 (de) 2011-04-15
PT2167470E (pt) 2011-05-16
EP2167470A1 (en) 2010-03-31
SV2009003420A (es) 2010-04-26
CL2008001648A1 (es) 2008-10-10
ZA200908280B (en) 2010-07-28
HU0700395D0 (en) 2007-07-30
ME00958B (me) 2012-06-20
MX2009013209A (es) 2010-04-09
HN2009003357A (es) 2013-08-12
ES2363672T3 (es) 2011-08-11
CA2689612A1 (en) 2008-12-11
DE602008005589D1 (de) 2011-04-28
CO6270233A2 (es) 2011-04-20
HK1138581A1 (en) 2010-08-27
WO2008149168A8 (en) 2010-01-07
HRP20110332T1 (hr) 2011-06-30
DK2167470T3 (da) 2011-06-27

Similar Documents

Publication Publication Date Title
CY1111644T1 (el) Τριαζολο [1,5-α] κινολινες ως συνδετες του υποδοχεα a3 της αδενοσινης
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
HRP20070076A2 (en) Pyrimidine derivatives
EA201170771A1 (ru) Органические соединения
CY1115866T1 (el) Τριαζολοπυριμιδινες
EA201400701A1 (ru) Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk)
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
ECSP10010197A (es) Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
EA201000614A1 (ru) Производные пурина как лиганды аденозинового рецептора а
AR048069A1 (es) Derivados de pirazolo con heteroarilo fusionado
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
CY1109369T1 (el) Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
CY1107875T1 (el) Παραγωγα αμινοκινολινης και η χρηση τους ως συνδετες των α3 αδενοσινης
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
EA200400848A1 (ru) Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
AR048501A1 (es) Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla
DK1742950T3 (da) Pyrazolo-[4,3-D]-pyrimidiner
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
DK1836151T3 (da) D-vitamin-receptormodulatorer
EA200970426A1 (ru) Селективный агонист tr-бета 1